Deleted In Cancer 1 (DICE1): Search for a function in prostate carcinoma (PCa)

2007 ◽  
Vol 25 (18_suppl) ◽  
pp. 15634-15634
Author(s):  
S. Filleur ◽  
I. Wieland ◽  
T. Nelius ◽  
R. Kennedy ◽  
W. De Riese ◽  
...  

15634 Background: Recently, DICE1 gene (MIM 604331 ) was identified to colocalize with the microsatellite marker D13S284 in 13q14.3, a region frequently affected by allelic deletion in PCa. We previously showed that DICE1 mRNA expression is down-regulated in PCa cell lines compared to normal prostate tissue, due to DICE1 promoter hypermethylation; suggesting that DICE1 is a tumor suppressor gene. Methods: Human PCa cell lines PC3 and DU145 were lipo-transfected with mammalian expression plasmids encoding for the full length DICE1 gene or for its N- (APAI construct) and C-terminal (DEAD construct) fragments. The constructs expression was determined by semi-quantitative PCR and quantified by Real-time PCR. Clonogenic formation and apoptotic assays were performed. Results: The PCR analysis showed that the expression of DICE1, APAI and DEAD domains in transfected PC3 and DU145 cell lines was increased 30.6, 75.2 and 27.9 fold in PC3 cells and 4.3, 5 and 2.5 fold in DU145 cells, respectively, compared to non-transfected cells. The function analysis showed that the ectopic expression of DICE1 suppressed clonogenic growth of PC3 and DU145 cell lines. Surprisingly, we showed that like DICE1, DEAD and APAI inhibit the PC3 and DU145 clonogenic growth suggesting that both regions are involved in prostate tumor growth inhibition. The apoptosis assay could not show any DNA fragmentation activity for DICE1. Conclusions: We demonstrated that DICE1 is a tumor suppressor in PCa. DICE1 mRNA expression is down-regulated in PCa cell lines compared to normal prostate tissue and its ectopic expression in PCa cell lines inhibits their capacity to form clonogenic colonies in vitro. The functional analysis could not reveal any role of DICE1 in PCa apoptosis, suggesting that other molecular mechanisms are involved. No significant financial relationships to disclose.

2005 ◽  
Vol 173 (4S) ◽  
pp. 125-125
Author(s):  
Christopher Haqq ◽  
R. Li ◽  
Thomas M. Wheeler ◽  
M. Sayeeduddin ◽  
Gustavo Ayala

2015 ◽  
Vol 205 (6) ◽  
pp. W585-W593 ◽  
Author(s):  
Tristan Barrett ◽  
Andrew N. Priest ◽  
Edward M. Lawrence ◽  
Debra A. Goldman ◽  
Anne Y. Warren ◽  
...  

PLoS ONE ◽  
2019 ◽  
Vol 14 (4) ◽  
pp. e0214588
Author(s):  
Melissa S. DeRycke ◽  
Melissa C. Larson ◽  
Asha A. Nair ◽  
Shannon K. McDonnell ◽  
Amy J. French ◽  
...  

2008 ◽  
Vol 6 (9) ◽  
pp. 109-110
Author(s):  
A. Fiszer-Kierzkowska ◽  
E. Malusecka ◽  
M. Jarzab ◽  
M. Gawkowska-Suwinska ◽  
J. Rembak-Szynkiewicz ◽  
...  

2016 ◽  
Vol 34 (2_suppl) ◽  
pp. 298-298
Author(s):  
Kathryn M Wilson ◽  
Travis Gerke ◽  
Ericka Ebot ◽  
Jennifer A Sinnott ◽  
Jennifer R. Rider ◽  
...  

298 Background: We previously found that vasectomy was associated with an increased risk of prostate cancer, and particularly, risk of lethal prostate cancer in the Health Professionals Follow-up Study (HPFS). However, the possible biological basis for this finding is unclear. In this study, we explored possible biological mechanisms by assessing differences in gene expression in the prostate tissue of men with and without a history of vasectomy prostate cancer diagnosis. Methods: Within the HPFS, vasectomy data and gene expression data (20,254 genes) was available from archival tumor tissue from 263 cases, 124 of whom also had data for adjacent normal tissue. To relate expression of individual genes to vasectomy we used linear regression adjusting for age and year at diagnosis. We ran gene set enrichment analysis to identify pathways of genes associated with vasectomy. Results: Among 263 cases, 67 (25%) reported a vasectomy prior to cancer diagnosis. Mean age at diagnosis was 66 years among men without and 65 years among men with vasectomy. Median time between vasectomy and prostate cancer diagnosis was 25 years. Gene expression in tumor tissue was not associated with vasectomy status. In adjacent normal tissue, three individual genes were associated with vasectomy with Bonferroni-corrected p-values of < 0.10: RAPGEF6, OR4C3, and SLC35F4. Gene set enrichment analysis found five pathways upregulated and seven pathways downregulated in men with vasectomy compared to those without in normal prostate tissue with a FDR < 0.05. Upregulated pathways included several immune-related gene sets and G-protein-coupled receptor gene sets. Conclusions: We identified significant differences in gene expression profiles in normal prostate tissue according to vasectomy status among men treated for prostate cancer. The fact that such differences existed several decades after vasectomy provides support for the idea that vasectomy may play a role in the etiology of prostate cancer.


2013 ◽  
Vol 3 ◽  
pp. 41 ◽  
Author(s):  
Vikram S. Dogra ◽  
Bhargava K. Chinni ◽  
Keerthi S. Valluru ◽  
Jean V. Joseph ◽  
Ahmed Ghazi ◽  
...  

Objective: The objective of this study is to validate if ex-vivo multispectral photoacoustic (PA) imaging can differentiate between malignant prostate tissue, benign prostatic hyperplasia (BPH), and normal human prostate tissue. Materials and Methods: Institutional Review Board's approval was obtained for this study. A total of 30 patients undergoing prostatectomy for biopsy-confirmed prostate cancer were included in this study with informed consent. Multispectral PA imaging was performed on surgically excised prostate tissue and chromophore images that represent optical absorption of deoxyhemoglobin (dHb), oxyhemoglobin (HbO2), lipid, and water were reconstructed. After the imaging procedure is completed, malignant prostate, BPH and normal prostate regions were marked by the genitourinary pathologist on histopathology slides and digital images of marked histopathology slides were obtained. The histopathology images were co-registered with chromophore images. Region of interest (ROI) corresponding to malignant prostate, BPH and normal prostate were defined on the chromophore images. Pixel values within each ROI were then averaged to determine mean intensities of dHb, HbO2, lipid, and water. Results: Our preliminary results show that there is statistically significant difference in mean intensity of dHb (P < 0.0001) and lipid (P = 0.0251) between malignant prostate and normal prostate tissue. There was difference in mean intensity of dHb (P < 0.0001) between malignant prostate and BPH. Sensitivity, specificity, positive predictive value, and negative predictive value of our imaging system were found to be 81.3%, 96.2%, 92.9% and 89.3% respectively. Conclusion: Our preliminary results of ex-vivo human prostate study suggest that multispectral PA imaging can differentiate between malignant prostate, BPH and normal prostate tissue.


2019 ◽  
Vol 20 (7) ◽  
pp. 1697 ◽  
Author(s):  
Yoshihisa Tokumaru ◽  
Toshihiro Tajirika ◽  
Nobuhiko Sugito ◽  
Yuki Kuranaga ◽  
Haruka Shinohara ◽  
...  

Gastric cancer (GC) is one of the most common cancers worldwide. In the clinical setting, the identification of HER2 overexpression in GC was a significant finding, as trastuzumab, an anti-HER2 drug, provides a survival advantage to HER2-positive GC patients. In HER2-postive GC, the dysregulation of PI3K/AKT and MAPK/ERK signaling pathways has been reported, and inhibition of these pathways is an important therapeutic strategy. MiR-143 is known to act as a tumor suppressor in several cancers, such as bladder cancer, breast cancer, colorectal cancer, and gastric cancer. In the current study, we developed a novel chemically-modified miR-143 and explored the functions of this synthetic miR-143 (syn-miR-143) in HER2-positive gastric cancer. The expression level of miR-143 was down-regulated in GC cell lines, including HER2-positive GC cell lines, MKN7, and KATO-III. The ectopic expression of miR-143 in those cell lines suppressed cell growth through systemic silencing of KRAS and its effector signaling molecules, AKT and ERK. Furthermore, syn-miR-143 indirectly down-regulated the expression of HER2, an upstream molecule of KRAS, through silencing DEAD/H-box RNA helicase 6 (DDX6), RNA helicase, which enhanced HER2 protein expression at the translational step in HER2-positive GC cells. These findings suggested that syn-miR-143 acted as a tumor suppressor through the impairment of KRAS networks including the DDX6.


Sign in / Sign up

Export Citation Format

Share Document